-
公开(公告)号：KR1020130079952A
公开(公告)日：2013-07-11
申请号：KR1020120000742
申请日：2012-01-03
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/6893 , C12Q1/6883 , C12Q2600/158 , G01N33/5302 , G01N2800/042
Abstract: PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict DR progression by measuring and comparing the expression level of genes or proteins of which expression is reduced in a patient with DR. CONSTITUTION: A composition for diagnosing DR contains an agent which measures mRNA level or protein level of one or more genes selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of the genes or proteins selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H; and comparing the expression level with the expression level of a control group sample.
Abstract translation: 目的：提供早期诊断糖尿病视网膜病变（DR）的早期诊断指标，并通过测量和比较DR患者中表达降低的基因或蛋白质的表达水平来显着预测DR进展。 构成：用于诊断DR的组合物含有测定选自凝血酶原，载脂蛋白A1，α-2-巨球蛋白和补体因子H的一种或多种基因的mRNA水平或蛋白质水平的试剂。用于诊断DR的试剂盒包含 组成。 用于提供用于诊断DR的信息的方法包括以下步骤：测量选自凝血酶原，载脂蛋白A1，α-2-巨球蛋白和补体因子H的基因或蛋白质的表达水平; 并将表达水平与对照组样品的表达水平进行比较。
-
公开(公告)号：KR1020130079951A
公开(公告)日：2013-07-11
申请号：KR1020120000741
申请日：2012-01-03
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/164 , G01N2800/50 , G01N2800/60 , G01N33/5302
Abstract: PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict or understand DR progression by measuring and comparing the expression level of genes or proteins of which expression level is reduced in a patient with DR. CONSTITUTION: A composition for diagnosing DR contains an agent for measuring mRNA or protein level of one or more genes selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of one or more genes or proteins selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H; and comparing the expression level with the expression level of a control group sample.
Abstract translation: 目的：提供早期诊断糖尿病性视网膜病变（DR）的标志物，以早期诊断DR，并通过测量和比较DR患者中表达水平降低的基因或蛋白质的表达水平来显着预测或了解DR进展。 构成：用于诊断DR的组合物含有用于测量选自凝血酶原，载脂蛋白A1，α-2-巨球蛋白和补体因子H的一种或多种基因的mRNA或蛋白质水平的试剂。用于诊断DR的试剂盒含有 组成。 提供用于诊断DR的信息的方法包括以下步骤：测量选自由凝血酶原，载脂蛋白A1，α-2-巨球蛋白和补体因子H组成的组中的一种或多种基因或蛋白质的表达水平; 并将表达水平与对照组样品的表达水平进行比较。
-
23.发明公开ＵＶ ｐｈｏｔｏｍｅｔｒｙ를 이용한 혈액 내의 고발현 단백질의 제거 또는 저발현 단백질의 회수 효율을 실시간으로 모니터하는 방법 有权通过紫外分光光度法实时监测高渗血液蛋白质或回收低渗血液蛋白质
公开(公告)号：KR1020120010991A
公开(公告)日：2012-02-06
申请号：KR1020110074311
申请日：2011-07-26
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/582
Abstract: PURPOSE: A method for monitoring efficiency for removing highly expressed proteins and/or collecting lowly expressed proteins from blood in real-time is provided. CONSTITUTION: A method for monitoring efficiency of removing highly expressed proteins or lowerly expressed proteins in blood comprises: a step of binding fluorescence or UV marker with the proteins in a blood sample; and a step of passing the blood sample through a column for removing highly expressed proteins. The fluorescence or UV marker is a GFP(green fluorescent protein), mGFP(modified GFP), EGFP(enhanced GFP), RFP(red fluorescent protein), mRFP, ERFP, BFP(blue fluorescent protein), EBFP, YFP(yellow fluorescent protein), EYFP, CFP(cyan fluorescent protein), or ECFP.
Abstract translation: 目的：提供一种监测从血液中实时清除高表达蛋白质和/或收集低表达蛋白质的效率的方法。 构成：监测去除高表达蛋白质或血液中低表达蛋白质的效率的方法，包括：将荧光或UV标记物与血液样品中的蛋白质结合的步骤; 以及使血液样品通过用于除去高度表达的蛋白质的柱的步骤。 荧光或UV标记是GFP（绿色荧光蛋白），mGFP（修饰GFP），EGFP（增强GFP），RFP（红色荧光蛋白），mRFP，ERFP，BFP（蓝色荧光蛋白），EBFP，YFP（黄色荧光 蛋白质），EYFP，CFP（青色荧光蛋白）或ECFP。
-
Patent Agency Ranking
-
公开(公告)号：KR101923496B1
公开(公告)日：2018-11-29
申请号：KR1020160117997
申请日：2016-09-13
Applicant: 서울대학교산학협력단
IPC: H01G11/62 , C08L101/12 , C08L33/20 , C08L25/18 , C08L79/08
CPC classification number: Y02E60/13
Abstract: 본발명은고전압초고용량커패시터용수소결합을이용한준고체상유연성이온성액체및 가교고분자복합전해질에관한것으로서, 보다상세하게는하이드록시, 페놀등 수소결합이가능한관능기를가진고분자를사용하여이온성액체를섞어가교결합을시키게되면가교고분자의관능기의수소와가교의수소가이온성액체의음이온과수소결합을이루어전기화학적안정성을개선시킴으로써고전압초고용량커패시터용전해질로유용하게사용될수 있다.
-
公开(公告)号：KR101343137B1
公开(公告)日：2013-12-20
申请号：KR1020120000741
申请日：2012-01-03
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/164 , G01N2800/50 , G01N2800/60
Abstract: 본발명은당뇨망막병증(diabetic retinopathy) 진단용조성물및 당뇨망막병증진단용키트에관한것이다. 또한, 본발명은당뇨망막병증진단에필요한정보를제공하기위한분석방법에관한것이다. 상기에서기술한바와같이, 본발명은당뇨망막병증을조기에진단할수 있는마커를제공함으로써, 당뇨망막병증환자에게서발현이감소한유전자또는그 단백질의발현수준을측정및 비교하여당뇨망막병증의조기진단및 질병정도를유의적으로예측또는파악할수 있다. 아울러, 본발명의마커는비침습성진단을가능하게하는바, 혈액, 뇨검사등으로간단하고유효성있는당뇨망막병증의바이오마커를이용한진단방법이개발되면가정및 일반의원에서의조기발견에매우유용할것이며, 국가적인관점에서의료비절감효과를가지고올 수있다.
-
公开(公告)号：KR101343286B1
公开(公告)日：2013-12-18
申请号：KR1020120000743
申请日：2012-01-03
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/164 , G01N2800/50 , G01N2800/60
Abstract: 본발명은당뇨망막병증(diabetic retinopathy) 진단용조성물및 당뇨망막병증진단용키트에관한것이다. 또한, 본발명은당뇨망막병증진단에필요한정보를제공하기위한분석방법에관한것이다. 상기에서기술한바와같이, 본발명은당뇨망막병증을조기에진단할수 있는마커를제공함으로써, 당뇨망막병증환자에게서발현이감소한유전자또는그 단백질의발현수준을측정및 비교하여당뇨망막병증의조기진단및 질병정도를유의적으로예측또는파악할수 있다. 아울러, 본발명의마커는비침습성진단을가능하게하는바, 혈액, 뇨검사등으로간단하고유효성있는당뇨망막병증의바이오마커를이용한진단방법이개발되면가정및 일반의원에서의조기발견에매우유용할것이며, 국가적인관점에서의료비절감효과를가지고올 수있다.
Abstract translation: 本发明涉及用于诊断糖尿病视网膜病的组合物和用于诊断糖尿病视网膜病的药盒。 本发明还涉及提供诊断糖尿病视网膜病变所需信息的分析方法。 如上所述，本发明通过提供一种标记，可以在早期阶段诊断的糖尿病性视网膜病，基因或蛋白质表达的表达水平被从所测量的糖尿病性视网膜病和下降相比早期糖尿病视网膜病变诊断 并且可以显着预测或理解疾病的程度。 另外，本发明的标记物是在早期发现eseoui家庭和如果简单一般诊所非常有用的，使用验证由酒吧，血液和尿液检查开发糖尿病性视网膜病的诊断方法，例如，生物标记物，以使非侵入性诊断 从全国的角度来看，可以降低医疗费用。
-
公开(公告)号：KR1020130116433A
公开(公告)日：2013-10-24
申请号：KR1020120027653
申请日：2012-03-19
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/6893 , C12Q1/6886 , C12Q2600/118 , G01N33/5302 , G01N2800/067
Abstract: PURPOSE: A marker for diagnosing pancreatic cancer is provided to early diagnose pancreatic cancer by combination according to specificity and sensitivity. CONSTITUTION: A marker for diagnosing pancreatic cancer is selected among alpha-1-anti chymotrypsin, alpha-1-antitrypsin, alpha-2-macroglobulin, ceruloplasmin, complement factor B, complement C4A, complement C4 gamma chain, complement C9, haptoglobin, hemopexin, kininogen, plasma protease C1 inhibitor, thyroxine binding globulin, transferrin, vitronectin, zinc alpha-2-glycoprotein, apolipoprotein A1, apolipoprotein A2, apolipoprotein A4, gelsolin, inter-alpha-trypsin inhibitor heavy chain H1, and pigment epithelium derived factor. Pancreatic cancer is diagnosed using a tissue, whole blood, plasma, or serum.
Abstract translation: 目的：根据特异性和敏感性，通过组合提供诊断胰腺癌的标志物，以早期诊断胰腺癌。 构成：用于诊断胰腺癌的标志物选自α-1-抗胰凝乳蛋白酶，α-1-抗胰蛋白酶，α-2-巨球蛋白，血浆铜蓝蛋白，补体因子B，补体C4A，补体C4γ链，补体C9，触珠蛋白，血红蛋白 ，激肽原，血浆蛋白酶C1抑制剂，甲状腺素结合球蛋白，转铁蛋白，玻连蛋白，α-2-糖蛋白，载脂蛋白A1，载脂蛋白A2，载脂蛋白A4，凝溶胶蛋白，α间胰蛋白酶抑制剂重链H1和色素上皮衍生因子。 使用组织，全血，血浆或血清诊断胰腺癌。
-
-
-
-
-
-
-
Search Results
28
records
(took 0.025 seconds)
